Why Vitamin D may not calm MS immune cells in some people

Credibility

Interest

Share:2 min read

Key Takeaway

A common MS-linked gene change can stop vitamin D from helping immune cells become calming 'Tr1' cells, which may make MS inflammation harder to control.

What They Found

The researchers found that a specific change in the CD226 gene (called Gly307Ser) makes immune cells less able to switch into Tr1 cells when given vitamin D. Tr1 cells are a type of immune cell that produces IL-10, a calming chemical that helps reduce inflammation; vitamin D normally helps this switch happen. The CD226 change weakens activation of LFA-1, a molecule that acts like a sticky handshake between cells and helps the Tr1 type form. When LFA-1 doesn’t work well, the immune cells keep making inflammatory signals instead of calming ones, so vitamin D can’t do its usual job. They showed this effect both in lab-grown human T cells and in immune cells from people with MS who carry the CD226 risk version.

Who Should Care and Why

People with MS and their caregivers should care because this study helps explain why vitamin D might not help everyone the same way — some people have a gene version that blocks the benefit. Think of vitamin D as a coach trying to teach immune cells to calm down, and the CD226 change as a faulty whistle that stops the coach being heard. This finding matters for doctors too, because knowing a patient’s CD226 type could help explain treatment responses or guide personalized care. Patients on vitamin D supplements shouldn’t stop them, but this suggests supplements alone may not fix immune imbalance for everyone. Caregivers can use this information to discuss with clinicians whether genetic testing or different treatment strategies might be helpful.

Important Considerations

The study was done mainly in cells grown in the lab and in samples from people, so it does not prove what happens inside the whole body over time. Not every person with MS has the CD226 risk version, so these results apply only to those who carry that specific gene change. This research shows a likely reason for reduced benefit from vitamin D in some people, but it doesn’t yet change treatment rules or prove that testing will improve care.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Genetics Early Research MS Progression

Article Topics:

AutoimmunityImmunologyInflammationMultiple sclerosisT cellsTregs

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like The Journal of clinical investigation often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News